Vistagen Therapeutics Inc (VTGN) Director Jon S. Saxe Buys 12,080 Shares of Stock

Vistagen Therapeutics Inc (NASDAQ:VTGN) Director Jon S. Saxe acquired 12,080 shares of the company’s stock in a transaction dated Wednesday, March 13th. The shares were bought at an average price of $1.26 per share, for a total transaction of $15,220.80. Following the acquisition, the director now owns 3,251 shares in the company, valued at approximately $4,096.26. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

NASDAQ VTGN traded down $0.01 on Friday, reaching $1.27. The company’s stock had a trading volume of 495,400 shares, compared to its average volume of 272,780. The stock has a market cap of $54.55 million, a P/E ratio of -1.14 and a beta of -0.34. Vistagen Therapeutics Inc has a 52 week low of $0.81 and a 52 week high of $2.44.

Vistagen Therapeutics (NASDAQ:VTGN) last posted its earnings results on Tuesday, February 12th. The company reported ($0.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.02). As a group, equities analysts predict that Vistagen Therapeutics Inc will post -0.9 EPS for the current year.

A number of analysts recently weighed in on the stock. ValuEngine cut shares of Vistagen Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Maxim Group reissued a “buy” rating and issued a $6.00 target price on shares of Vistagen Therapeutics in a research note on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $8.30.

A number of institutional investors have recently modified their holdings of the business. D.A. Davidson & CO. grew its stake in Vistagen Therapeutics by 22.9% during the fourth quarter. D.A. Davidson & CO. now owns 94,000 shares of the company’s stock worth $141,000 after buying an additional 17,500 shares during the last quarter. Geode Capital Management LLC grew its stake in Vistagen Therapeutics by 13.0% during the fourth quarter. Geode Capital Management LLC now owns 154,457 shares of the company’s stock worth $231,000 after buying an additional 17,721 shares during the last quarter. Millennium Management LLC bought a new stake in Vistagen Therapeutics during the fourth quarter worth about $28,000. Northern Trust Corp grew its stake in Vistagen Therapeutics by 168.6% during the fourth quarter. Northern Trust Corp now owns 69,642 shares of the company’s stock worth $104,000 after buying an additional 43,714 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in Vistagen Therapeutics by 42.7% during the third quarter. Vanguard Group Inc. now owns 257,465 shares of the company’s stock worth $373,000 after buying an additional 77,090 shares during the last quarter. 9.97% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://transcriptdaily.com/2019/03/15/vistagen-therapeutics-inc-vtgn-director-jon-s-saxe-buys-12080-shares-of-stock.html.

Vistagen Therapeutics Company Profile

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Recommended Story: Different Options Trading Strategies

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.